Published in Cancer Res on March 15, 2007
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res (2008) 3.98
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine. Br J Cancer (2010) 3.25
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol (2009) 3.24
The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer (2012) 2.79
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch (2008) 2.78
Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol (2012) 2.74
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer (2011) 2.68
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol (2009) 2.48
Colorectal cancer molecular biology moves into clinical practice. Gut (2010) 2.32
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer (2011) 2.24
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest (2011) 2.20
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One (2009) 2.18
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer (2011) 2.16
For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res (2012) 2.09
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene (2010) 1.88
High frequency of BRAF V600E mutations in ameloblastoma. J Pathol (2014) 1.79
The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res (2008) 1.68
High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med (2010) 1.68
Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer (2009) 1.68
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A (2008) 1.66
Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets (2007) 1.44
Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One (2010) 1.41
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.38
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer (2012) 1.31
Targeted therapies: how personal should we go? Nat Rev Clin Oncol (2011) 1.31
Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol (2011) 1.31
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther (2011) 1.31
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer (2015) 1.28
Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines. PLoS One (2013) 1.27
Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One (2011) 1.27
Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem (2012) 1.26
A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist (2010) 1.26
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol (2009) 1.24
Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer (2011) 1.24
KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer (2010) 1.22
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer (2009) 1.22
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest (2014) 1.21
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer (2009) 1.16
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci U S A (2011) 1.16
KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. Br J Cancer (2012) 1.16
Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf) (2013) 1.15
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer (2007) 1.15
KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS One (2012) 1.14
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer (2012) 1.13
A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer (2008) 1.13
Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res (2013) 1.12
Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer (2010) 1.11
Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist (2011) 1.11
Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. J Hematol Oncol (2009) 1.09
The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS One (2013) 1.08
Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res (2008) 1.07
Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst (2011) 1.06
KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. Curr Oncol (2010) 1.05
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol (2011) 1.04
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br J Cancer (2011) 1.04
PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol (2009) 1.04
Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem (2008) 1.04
KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol (2009) 1.04
EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics (2009) 1.03
Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations. PLoS One (2013) 1.00
Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One (2013) 0.99
Biomarker use in colorectal cancer therapy. J Natl Compr Canc Netw (2011) 0.99
The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain. BMC Med Genet (2011) 0.98
KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn (2008) 0.98
Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol (2014) 0.97
Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer (2008) 0.97
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist (2011) 0.97
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. J Transl Med (2012) 0.97
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study. PLoS One (2012) 0.96
Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. Cancer Biol Ther (2014) 0.96
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw (2011) 0.95
EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics (2009) 0.95
MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1. PLoS One (2013) 0.95
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis (2015) 0.94
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. Int J Clin Oncol (2012) 0.94
Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol (2010) 0.93
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics. J Ovarian Res (2010) 0.93
Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer. Br J Cancer (2013) 0.93
BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget (2014) 0.92
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. J Transl Med (2012) 0.92
Associations of anthropometric factors with KRAS and BRAF mutation status of primary colorectal cancer in men and women: a cohort study. PLoS One (2014) 0.92
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer (2011) 0.92
Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. Oncologist (2010) 0.92
MicroRNAs targeting EGFR signalling pathway in colorectal cancer. J Cancer Res Clin Oncol (2013) 0.91
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer. BMC Cancer (2011) 0.91
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med (Berl) (2014) 0.91
A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. Cancer Chemother Pharmacol (2010) 0.91
Hurdles in anticancer drug development from a regulatory perspective. Nat Rev Clin Oncol (2012) 0.90
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. J Cancer Res Clin Oncol (2012) 0.90
Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World J Gastroenterol (2014) 0.90
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. Br J Cancer (2014) 0.90
ERBBs in the gastrointestinal tract: recent progress and new perspectives. Exp Cell Res (2008) 0.89
Personalized therapies in the cancer "omics" era. Mol Cancer (2010) 0.88
Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World J Gastroenterol (2014) 0.88
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
International network of cancer genome projects. Nature (2010) 20.35
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 12.00
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med (2013) 11.93
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol (2007) 11.04
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol (2010) 5.10
Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet (2009) 5.06
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 4.67
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol (2013) 4.04
A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat Genet (2011) 3.94
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov (2011) 3.86
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst (2002) 3.54
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A (2004) 3.35
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol (2012) 3.04
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov (2013) 2.87
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res (2013) 2.61
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol (2008) 2.57
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet (2010) 2.56
Identification of low-frequency variants associated with gout and serum uric acid levels. Nat Genet (2011) 2.48
Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol (2008) 2.44
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol (2008) 2.40
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol (2006) 2.38
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res (2011) 2.27
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol (2007) 2.19
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One (2009) 2.18
HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist (2005) 2.17
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol (2012) 2.15
Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol (2005) 2.10
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res (2013) 2.03
Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat Genet (2002) 2.00
Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res (2007) 1.98
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol (2012) 1.97
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer (2009) 1.94
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther (2004) 1.90
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol (2010) 1.80
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med (2014) 1.79